Agenda
8:05 AM — 10:35 AM
Session 1 - Opening Plenary Session10:55 AM — 12:05 PM
Session 2 - Diabetic Drug Development and CV Safety1:05 PM — 2:15 PM
Session 2 (Continued) - Diabetic Drug Development and CV Safety2:15 PM — 2:45 PM
Abstract Presentations3:05 PM — 3:45 PM
Session 3 - Approaches To Clinical Analysis of CV Risk3:45 PM — 4:25 PM
Session 4 - Novel Clinical Trial Approaches4:25 PM — 4:55 PM
Panel Discussion - Design Considerations8:00 AM — 9:35 AM
Session 5 - Preclinical Assessment11:45 AM — 12:35 PM
Session 7 - Post-Marketing Assessment – State Of The Art1:35 PM — 1:50 PM
Concluding Remarks1:50 PM — 2:05 PM
Final CommentsHave an account?